Combining Classic and Novel Neutrophil-Related Biomarkers to Identify Non-Small-Cell Lung Cancer
Open Access
Abstract
Background: Recent studies have revealed that neutrophils play a crucial role in cancer progression. This study aimed to explore the diagnostic value of neutrophil-related biomarkers for non-small-cell lung cancer (NSCLC). Methods: We initially assessed the associations between classic neutrophil-related biomarkers (neutrophil-to-lymphocyte ratio (NLR), absolute neutrophil counts (NEU), absolute lymphocyte counts (LYM)) and NSCLC in 3942 cases and 6791 controls. Then, we measured 11 novel neutrophil-related biomarkers via Luminex Assays in 132 cases and 66 controls, individually matching on sex and age (±5 years), and evaluated their associations with NSCLC risk. We also developed the predictive models by sequentially adding variables of interest and assessed model improvement. Results: Interleukin-6 (IL-6) (odds ratio (OR) = 10.687, 95% confidence interval (CI): 3.875, 29.473) and Interleukin 1 Receptor Antagonist (IL-1RA) (OR = 8.113, 95% CI: 3.182, 20.689) shows strong associations with NSCLC risk after adjusting for body mass index, smoking status, NLR, and carcinoembryonic antigen. Adding the two identified biomarkers to the predictive model significantly elevated the model performance from an area under the receiver operating characteristic curve of 0.716 to 0.851 with a net reclassification improvement of 97.73%. Conclusions: IL-6 and IL-1RA were recognized as independent risk factors for NSCLC, improving the predictive performance of the model in identifying disease.Keywords
Funding Information
- Key Laboratory of Intelligent Preventive Medicine of Zhejiang Province (2020E10004, 2019R01007, 2020C03002, K20230085)
- Leading Innovative and Entrepreneur Team Introduction Program of Zhejiang (2020E10004, 2019R01007, 2020C03002, K20230085)
- Key Research and Development Program of Zhejiang Province (2020E10004, 2019R01007, 2020C03002, K20230085)
- Healthy Zhejiang One Million Cohort (2020E10004, 2019R01007, 2020C03002, K20230085)
This publication has 58 references indexed in Scilit:
- Circulating Inflammation Markers and Prospective Risk for Lung CancerJNCI: Journal of the National Cancer Institute, 2013
- Serum interleukin‐6 associated with hepatocellular carcinoma risk: A nested case–control studyInternational Journal of Cancer, 2013
- Mast cell and macrophage chemokines CXCL1/CXCL2 control the early stage of neutrophil recruitment during tissue inflammationBlood, 2013
- Neutrophil recruitment and function in health and inflammationNature Reviews Immunology, 2013
- Circulating interleukin‐6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapyInternational Journal of Cancer, 2012
- C-Reactive Protein, Interleukin 6 and Lung Cancer Risk: A Meta-AnalysisPLOS ONE, 2012
- Neutrophils in the activation and regulation of innate and adaptive immunityNature Reviews Immunology, 2011
- Increased Levels of Circulating Interleukin 6, Interleukin 8, C-Reactive Protein, and Risk of Lung CancerJNCI: Journal of the National Cancer Institute, 2011
- Serum Concentrations of Cytokines and Lung Cancer Survival in African Americans and CaucasiansCancer Epidemiology, Biomarkers & Prevention, 2009
- Allele 2 of the interleukin-1 receptor antagonist gene (IL1RN*2) is associated with a decreased risk of primary lung cancerCancer Letters, 2006